Antiaromatase agents: preclinical data and neoadjuvant therapy

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Estrogen plays a key role in the development and progression of hormone-sensitive breast cancers.
• Aromatase is a critical enzyme responsible for estrogen biosynthesis in postmenopausal women.

Purpose of the Study:

• To evaluate the efficacy of exemestane as a potent and specific aromatase inactivator.
• To assess the impact of exemestane on peripheral and local estrogen production in postmenopausal women.
• To investigate the antitumor effects of exemestane in hormone-sensitive breast cancers.

Main Methods:

• Exemestane's inhibitory activity was tested in vitro using placental microsomes, breast cancer homogenates, and mammary fibroblasts.
• Postmenopausal women received daily milligram doses of exemestane.
• Aromatase activity in breast tumors and surrounding tissue was assessed.
• Tumor response was evaluated using mammography in the neoadjuvant setting.

Main Results:

• Exemestane demonstrated potent and specific aromatase inhibition with IC50 values in the nanomolar range.
• Exemestane administration led to near-complete blockade of peripheral aromatase and reduced circulating estrogens to undetectable levels.
• Significant inhibition of in situ aromatase activity was observed in both breast cancers and adjacent nonmalignant breast tissue.
• Antitumor effects, including tumor resolution on mammography, were noted in postmenopausal women with estrogen receptor-rich cancers following exemestane treatment.

Conclusions:

• Exemestane effectively inhibits estrogen biosynthesis both peripherally and locally within the breast.
• This drug offers new therapeutic options for treating hormone-sensitive breast cancers in postmenopausal women.
• The ability to block estrogen production systemically and within the tumor microenvironment is a key advantage.